BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 8169003)

  • 1. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells.
    Wu HC; Hsieh JT; Gleave ME; Brown NM; Pathak S; Chung LW
    Int J Cancer; 1994 May; 57(3):406-12. PubMed ID: 8169003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis.
    Thalmann GN; Sikes RA; Wu TT; Degeorges A; Chang SM; Ozen M; Pathak S; Chung LW
    Prostate; 2000 Jul; 44(2):91-103 Jul 1;44(2). PubMed ID: 10881018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer.
    Thalmann GN; Anezinis PE; Chang SM; Zhau HE; Kim EE; Hopwood VL; Pathak S; von Eschenbach AC; Chung LW
    Cancer Res; 1994 May; 54(10):2577-81. PubMed ID: 8168083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer.
    Thalmann GN; Sikes RA; Chang SM; Johnston DA; von Eschenbach AC; Chung LW
    J Natl Cancer Inst; 1996 Jun; 88(12):794-801. PubMed ID: 8637045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines.
    Wu TT; Sikes RA; Cui Q; Thalmann GN; Kao C; Murphy CF; Yang H; Zhau HE; Balian G; Chung LW
    Int J Cancer; 1998 Sep; 77(6):887-94. PubMed ID: 9714059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
    Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
    Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors.
    Gleave ME; Hsieh JT; Wu HC; von Eschenbach AC; Chung LW
    Cancer Res; 1992 Mar; 52(6):1598-605. PubMed ID: 1371718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autocrine regulation of prostate-specific antigen gene expression in a human prostatic cancer (LNCaP) subline.
    Hsieh JT; Wu HC; Gleave ME; von Eschenbach AC; Chung LW
    Cancer Res; 1993 Jun; 53(12):2852-7. PubMed ID: 7684949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
    Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
    Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human prostate cancer progression models and therapeutic intervention.
    Chung LW; Kao C; Sikes RA; Zhau HE
    Hinyokika Kiyo; 1997 Nov; 43(11):815-20. PubMed ID: 9436028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts.
    Gleave M; Hsieh JT; Gao CA; von Eschenbach AC; Chung LW
    Cancer Res; 1991 Jul; 51(14):3753-61. PubMed ID: 1712249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate and bone fibroblasts induce human prostate cancer growth in vivo: implications for bidirectional tumor-stromal cell interaction in prostate carcinoma growth and metastasis.
    Gleave ME; Hsieh JT; von Eschenbach AC; Chung LW
    J Urol; 1992 Apr; 147(4):1151-9. PubMed ID: 1372662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride.
    Umekita Y; Hiipakka RA; Kokontis JM; Liao S
    Proc Natl Acad Sci U S A; 1996 Oct; 93(21):11802-7. PubMed ID: 8876218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer.
    Gotoh A; Ko SC; Shirakawa T; Cheon J; Kao C; Miyamoto T; Gardner TA; Ho LJ; Cleutjens CB; Trapman J; Graham FL; Chung LW
    J Urol; 1998 Jul; 160(1):220-9. PubMed ID: 9628654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Permanent phenotypic and genotypic changes of prostate cancer cells cultured in a three-dimensional rotating-wall vessel.
    Rhee HW; Zhau HE; Pathak S; Multani AS; Pennanen S; Visakorpi T; Chung LW
    In Vitro Cell Dev Biol Anim; 2001 Mar; 37(3):127-40. PubMed ID: 11370803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malignant transformation in a nontumorigenic human prostatic epithelial cell line.
    Hayward SW; Wang Y; Cao M; Hom YK; Zhang B; Grossfeld GD; Sudilovsky D; Cunha GR
    Cancer Res; 2001 Nov; 61(22):8135-42. PubMed ID: 11719442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of wild type p53 function confers a hormone resistant phenotype on LNCaP prostate cancer cells.
    Burchardt M; Burchardt T; Shabsigh A; Ghafar M; Chen MW; Anastasiadis A; de la Taille A; Kiss A; Buttyan R
    Prostate; 2001 Sep; 48(4):225-30. PubMed ID: 11536301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human prostate fibroblasts induce growth and confer castration resistance and metastatic potential in LNCaP Cells.
    Thalmann GN; Rhee H; Sikes RA; Pathak S; Multani A; Zhau HE; Marshall FF; Chung LW
    Eur Urol; 2010 Jul; 58(1):162-71. PubMed ID: 19747763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.
    Raffo AJ; Perlman H; Chen MW; Day ML; Streitman JS; Buttyan R
    Cancer Res; 1995 Oct; 55(19):4438-45. PubMed ID: 7671257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen receptor modifications in prostate cancer cells upon long-termandrogen ablation and antiandrogen treatment.
    Marques RB; Erkens-Schulze S; de Ridder CM; Hermans KG; Waltering K; Visakorpi T; Trapman J; Romijn JC; van Weerden WM; Jenster G
    Int J Cancer; 2005 Nov; 117(2):221-9. PubMed ID: 15900601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.